Anaemia and Chronic Kidney Disease–Mineral and Bone Disorder: Pathophysiological Interactions, Stage-Wise Progression, and Clinical Implications – A Narrative Review
DOI:
https://doi.org/10.59675/U415Keywords:
chronic kidney disease; anaemia; CKD-MBD; fibroblast growth factor 23; ironAbstract
Background: Anaemia and chronic kidney disease–mineral and bone disorder (CKD-MBD) are prevalent complications of chronic kidney disease (CKD), and the interrelationship between these is often overstated. Several pathways, such as Klotho–vitamin D signalling, inflammation, parathyroid hormone (PTH) and iron–hepcidin signalling, offer potential areas of biological interaction, all of which develop in the same setting of declining kidney function.
Objective: This narrative review critically evaluates whether the association between anaemia and CKD-MBD reflects shared CKD progression, direct biological interaction, or clinically relevant consequences of combining these two diseases. This review focuses on human evidence for FGF23, iron–hepcidin signalling, PTH, vitamin D, and Klotho, and uses intervention studies to support therapeutic interdependence.
Methods: We conducted a focused narrative search of PubMed/MEDLINE up to 15 September 2026 using the following terms: CKD, anaemia, CKD-MBD, FGF23, hepcidin, PTH, vitamin D, and Klotho. We identified primary human studies, long-term cohorts, intervention studies, guidelines, and related mechanistic literature through targeted searching and screening of the reference list. We qualitatively synthesised evidence based on study design, consistency, longitudinality, adjustment for major confounders, and directness to the review question; these categories were not intended as a formal GRADE evaluation.
Results: The most consistent findings are that anaemia and CKD-MBD prevalence increase with declining kidney function, and that the clinical picture of these conditions becomes more complex. Human evidence for proposed intersections is best established for FGF23, where higher levels correlate with lower haemoglobin and incident anaemia in multiple cohorts, including prospective studies. However, iron-related factors modify this association and are sensitive to confounding by CKD severity and inflammation. The intersections between iron deficiency and hepcidin abnormalities with FGF23 biology are complex, and the clinical picture is variable. The possible relationships between PTH and vitamin D, anaemia, and response to erythropoietin, and the limited evidence for Klotho, are plausible. No intervention studies confirm whether correcting a CKD-MBD abnormality improves anaemia, or whether correcting anaemia meaningfully improves CKD-MBD.
Conclusion: The current literature supports a shared-pathophysiology model rather than a one-way causal model. Although FGF23 is one of the best-studied candidate biological intersections, it has not yet been shown to be causative or clinically significant in terms of synergy. Therefore, manage anaemia and CKD-MBD within comprehensive CKD management, and future longitudinal and intervention studies should evaluate whether specific pathways act independently and can be modified.
References
1. Kidney Disease: Improving Global Outcomes (KDIGO) Anaemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anaemia in Chronic Kidney Disease (CKD). Kidney Int. 2026;109(1S):S1-S99. doi:10.1016/j.kint.2025.06.006. PMID:41485812.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018. PMID:38490803.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001. PMID:30675420.
4. Carullo N, Sorbo D, Faga T, et al. Anaemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors. Int J Mol Sci. 2024;25(23):12838. doi:10.3390/ijms252312838. PMID:39684548.
5. Czaya B, Faul C. The Role of Fibroblast Growth Factor 23 in Inflammation and Anaemia. Int J Mol Sci. 2019;20(17):4195. doi:10.3390/ijms20174195. PMID:31461904.
6. Agoro R, White KE. Anaemia and fibroblast growth factor 23 elevation in CKD: homeostatic interactions and emerging therapeutics. Curr Opin Nephrol Hypertens. 2022;31(4):320-325. doi:10.1097/MNH.0000000000000797. PMID:35703246.
7. Sofue T, Nakagawa N, Kanda E, et al. Prevalence of anaemia in patients with CKD in Japan: J-CKD-DB. PLoS One. 2020;15(7):e0236132. doi:10.1371/journal.pone.0236132. PMID:32687544.
8. Ryu SR, Park SK, Jung JY, et al. The Prevalence and Management of Anaemia in Chronic Kidney Disease Patients: Results from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci. 2017;32(2):249-256. doi:10.3346/jkms.2017.32.2.249. PMID:28049235.
9. Saraf SL, Hsu JY, Ricardo AC, et al. Anaemia and Incident End-Stage Kidney Disease. Kidney360. 2020;1(7):623-630. doi:10.34067/kid.0000852020. PMID:33117990.
10. Bielesz B, Reiter T, Hammerle FP, et al. Role of Iron and Erythropoietin in association of FGF23 with anaemia in CKD in humans. J Clin Med. 2020;9(8):2640. doi:10.3390/jcm9082640. PMID:32823844.
11. Wojtaszek E, Glogowski T, Malyszko J. Iron and Chronic Kidney Disease: Still a Challenge. Front Med (Lausanne). 2020;7:565135. doi:10.3389/fmed.2020.565135. PMID:33392212.
12. Gamal M, Abdel-Rahman AM, Abd Elwahab A, et al. Serum hepcidin and erythropoietin in relation to anaemia in non-diabetic chronic kidney disease: a cross-sectional study. Sci Rep. 2026;16(1):28494. doi:10.1038/s41598-026-68785-z. PMID:42732007.
13. Tanaka M, Yoshida K, Fukuma S, et al. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anaemia: Results from the MBD-5D Study. PLoS One. 2016;11(10):e0164865. doi:10.1371/journal.pone.0164865. PMID:27764168.
14. Tanaka S, Kitamura H, Tsuruya K, et al. Prevalence, treatment status, and predictors of anaemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease. Clin Exp Nephrol. 2022;26(9):867-879. doi:10.1007/s10157-022-02227-8. PMID:35507237.
15. Shima H, Miya K, Okada K, et al. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anaemia in hemodialysis patients. BMC Res Notes. 2018;11:363. doi:10.1186/s13104-018-3483-6. PMID:29884226.
16. Nunes LLA, dos Reis LM, Osorio R, et al. High ferritin is associated with liver and bone marrow iron accumulation: Effects of 1-year deferoxamine treatment in hemodialysis-associated iron overload. PLoS One. 2024;19(8):e0306255. doi:10.1371/journal.pone.0306255. PMID:39121099.
17. Mehta R, Cai X, Hodakowski A, et al.; CRIC Study Investigators. Fibroblast growth factor 23 and anaemia in the Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol. 2017;12(11):1795-1803. doi:10.2215/CJN.03950417. PMID:28784656.
18. Nam KH, Kim H, An SY, et al. Circulating fibroblast growth factor-23 levels are associated with an increased risk of anaemia development in patients with nondialysis chronic kidney disease. Sci Rep. 2018;8:7294. doi:10.1038/s41598-018-25439-z. PMID:29740119.
19. Karava V, Dotis J, Kondou A, et al. Fibroblast growth factor 23 and vitamin D are associated with iron deficiency and anaemia in children with chronic kidney disease. Pediatr Nephrol. 2023;38(8):2771-2779. doi:10.1007/s00467-023-05903-3. PMID:36862253.
20. Li F, Ye X, Yang G, et al. Relationships between blood bone metabolic biomarkers and anaemia in patients with chronic kidney disease. Ren Fail. 2023;45(1):2210227. doi:10.1080/0886022X.2023.2210227. PMID:37170583.
21. Otsuki T, Utsunomiya K, Moriuchi M, et al. Effect of sucroferric oxyhydroxide on fibroblast growth factor 23 levels in hemodialysis patients. Nephron. 2018;140(3):161-168. doi:10.1159/000490903. PMID:29991053.
22. Patel NM, Gutierrez OM, Andress DL, et al. Vitamin D deficiency and anaemia in early chronic kidney disease. Kidney Int. 2010;77(8):715-720. doi:10.1038/ki.2009.537. PMID:20130525.
23. Tanaka M, Komaba H, Fukagawa M. Emerging association between parathyroid hormone and anaemia in hemodialysis patients. Ther Apher Dial. 2018;22(3):242-245. doi:10.1111/1744-9987.12685. PMID:29767854.
24. Xu Y, Peng H, Ke B. α-Klotho and anaemia in patients with chronic kidney disease: a new perspective. Exp Ther Med. 2017;14(6):5691-5695. doi:10.3892/etm.2017.5287. PMID:29250136.
25. Christodoulou M, Aspray TJ, Piec I, et al.; VDOP Trial Group. Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation. Age Ageing. 2024;53(5):afae096. doi:10.1093/ageing/afae096. PMID:38770543.
26. Mehta RC, Cho ME, Cai X, et al.; CRIC Study Investigators. Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int. 2021;100(6):1292-1302. doi:10.1016/j.kint.2021.07.013. PMID:34339746.
27. Scialla JJ, Xie H, Rahman M, et al.; CRIC Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25(2):349-360. doi:10.1681/ASN.2013050465. PMID:24158986.
28. Reimer KC, Nadal J, Meiselbach H, et al.; GCKD Study Investigators. Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort. Bone Res. 2023;11(1):52. doi:10.1038/s41413-023-00291-8. PMID:37857629.
29. Emarah SM, Ahmed MAR, El Kannishy GM, et al. Effect of vitamin D supplementation on management of anaemia in hemodialysis patients with vitamin D deficiency: A double-masked, randomised, controlled trial. Hemodial Int. 2024;28(1):51-58. doi:10.1111/hdi.13121. PMID:37853507.
30. Obi Y, Yamaguchi S, Hamano T, et al. Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomised clinical trial. Sci Rep. 2020;10(1):15500. doi:10.1038/s41598-020-72385-w. PMID:32968158.
31. Noonan ML, Clinkenbeard EL, Ni P, et al. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep. 2020;8(11):e14434. doi:10.14814/phy2.14434. PMID:32476270.
32. Noonan ML, Ni P, Agoro R, et al. The HIF-PHI BAY 85-3934 (Molidustat) improves anaemia and is associated with reduced levels of circulating FGF23 in a CKD mouse model. J Bone Miner Res. 2021;36(6):1117-1130. doi:10.1002/jbmr.4272. PMID:33592127.
33. Evenepoel P, Claes K, Meijers B, et al. Poor Vitamin K status is associated with low bone mineral density and Increased Fracture Risk in End-Stage Renal Disease. J Bone Miner Res. 2019;34(2):262-269. doi:10.1002/jbmr.3608. PMID:30427544.
34. Hung SC, Kuo KL, Peng CH, et al. Association of fluid retention with anaemia and clinical outcomes among patients with chronic kidney disease. J Am Heart Assoc. 2015;4(1):e001480. doi:10.1161/JAHA.114.001480. PMID:25559015.
35. Almanseekanaa LH, Ogaili RH, Baker SS. Interpretations of hematological findings among Iraqi children with celiac disease in Kerbala city. International Journal of Research in Pharmaceutical Sciences. 2019;10(1):641-4. doi:10.26452/ijrps.v10i1.1894.
36. Al-Nasrallah AA Gubair, Hade HA, Hamza HJ, Al-Shirifi MH. Physiological study of (IL-6 and IgG) immune responses related to iron deficiency patients in Babylon City. Aca Intl J Med Sci. 2025;1(1):91-95. doi:10.59675/M11.10.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Academic International Journal of Medical Update

This work is licensed under a Creative Commons Attribution 4.0 International License.

